Traws Pharma (TRAW) Competitors $1.50 -0.15 (-8.84%) As of 03:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TRAW vs. BLUE, IPSC, OTLK, TNYA, CNTB, AADI, ANEB, SKYE, STTK, and LTRNShould you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include bluebird bio (BLUE), Century Therapeutics (IPSC), Outlook Therapeutics (OTLK), Tenaya Therapeutics (TNYA), Connect Biopharma (CNTB), Aadi Bioscience (AADI), Anebulo Pharmaceuticals (ANEB), Skye Bioscience (SKYE), Shattuck Labs (STTK), and Lantern Pharma (LTRN). These companies are all part of the "pharmaceutical products" industry. Traws Pharma vs. bluebird bio Century Therapeutics Outlook Therapeutics Tenaya Therapeutics Connect Biopharma Aadi Bioscience Anebulo Pharmaceuticals Skye Bioscience Shattuck Labs Lantern Pharma bluebird bio (NASDAQ:BLUE) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, community ranking and risk. Does the media refer more to BLUE or TRAW? In the previous week, bluebird bio had 4 more articles in the media than Traws Pharma. MarketBeat recorded 6 mentions for bluebird bio and 2 mentions for Traws Pharma. Traws Pharma's average media sentiment score of 0.00 beat bluebird bio's score of -0.06 indicating that Traws Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment bluebird bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Traws Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, BLUE or TRAW? bluebird bio has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Do analysts recommend BLUE or TRAW? bluebird bio presently has a consensus price target of $44.60, suggesting a potential upside of 959.38%. Given bluebird bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe bluebird bio is more favorable than Traws Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score bluebird bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Traws Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor BLUE or TRAW? bluebird bio received 1041 more outperform votes than Traws Pharma when rated by MarketBeat users. CompanyUnderperformOutperformbluebird bioOutperform Votes104170.53% Underperform Votes43529.47% Traws PharmaN/AN/A Which has preferable valuation and earnings, BLUE or TRAW? Traws Pharma has lower revenue, but higher earnings than bluebird bio. bluebird bio is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratiobluebird bio$83.81M0.49-$211.91M-$45.54-0.09Traws Pharma$226K35.92-$18.95M-$40.90-0.04 Do insiders and institutionals have more ownership in BLUE or TRAW? 87.4% of bluebird bio shares are owned by institutional investors. Comparatively, 7.9% of Traws Pharma shares are owned by institutional investors. 1.4% of bluebird bio shares are owned by insiders. Comparatively, 13.6% of Traws Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is BLUE or TRAW more profitable? bluebird bio has a net margin of -565.74% compared to Traws Pharma's net margin of -62,294.25%. Traws Pharma's return on equity of 0.00% beat bluebird bio's return on equity.Company Net Margins Return on Equity Return on Assets bluebird bio-565.74% -322.46% -53.17% Traws Pharma -62,294.25%N/A -822.38% Summarybluebird bio beats Traws Pharma on 9 of the 17 factors compared between the two stocks. Get Traws Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRAW vs. The Competition Export to ExcelMetricTraws PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.12M$6.49B$5.36B$7.54BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-0.017.1022.1818.09Price / Sales35.92255.73395.26103.53Price / CashN/A65.6738.2034.62Price / Book0.136.286.714.14Net Income-$18.95M$142.49M$3.21B$247.68M7 Day Performance-19.60%11.41%6.26%6.30%1 Month Performance-43.66%-6.64%-6.00%-3.38%1 Year PerformanceN/A-2.03%15.13%3.13% Traws Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRAWTraws Pharma0.3332 of 5 stars$1.50-8.8%N/AN/A$7.58M$226,000.00-0.0117Gap UpBLUEbluebird bio2.3849 of 5 stars$4.45-6.5%$44.60+902.2%-77.2%$43.57M$83.81M-0.12520Analyst ForecastPositive NewsIPSCCentury Therapeutics1.8988 of 5 stars$0.50+0.6%$4.40+776.5%-82.3%$43.20M$6.59M-0.27170OTLKOutlook Therapeutics1.3145 of 5 stars$1.34-4.0%$10.20+664.0%-81.5%$42.74MN/A-0.1820Gap UpTNYATenaya Therapeutics3.0151 of 5 stars$0.49-0.7%$6.25+1,184.7%-89.7%$42.61MN/A-0.34110Gap UpCNTBConnect Biopharma2.7121 of 5 stars$0.77+18.1%$8.00+940.3%-48.2%$42.56M$24.12M0.00110Gap UpAADIAadi Bioscience0.9689 of 5 stars$1.71+4.3%$1.67-2.5%-18.4%$42.23M$25.07M-0.7540Positive NewsANEBAnebulo Pharmaceuticals2.5037 of 5 stars$1.01+6.4%$8.00+691.3%-63.4%$41.54MN/A-3.614SKYESkye Bioscience1.2795 of 5 stars$2.02-26.2%$16.60+723.8%-89.8%$41.51MN/A-1.9911Positive NewsGap UpSTTKShattuck Labs1.9954 of 5 stars$0.84-3.6%$7.50+788.8%-90.4%$40.42M$5.72M-0.55100LTRNLantern Pharma1.903 of 5 stars$3.69+4.5%$25.00+577.5%-39.7%$39.80MN/A-2.0720Positive News Related Companies and Tools Related Companies bluebird bio Competitors Century Therapeutics Competitors Outlook Therapeutics Competitors Tenaya Therapeutics Competitors Connect Biopharma Competitors Aadi Bioscience Competitors Anebulo Pharmaceuticals Competitors Skye Bioscience Competitors Shattuck Labs Competitors Lantern Pharma Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TRAW) was last updated on 4/23/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TRAW Stock Free TRAW Stock Alerts